This study investigated the anti-inflammatory effect of Astragaloside on rat intestinal epithelial cells (IEC-6) model induced by lipopolysaccharide (LPS). A model of IEC-6 cell inflammation induced by LPS was established, and the survival rate, the related inflammatory factors, genes and protein expression levels of inflammatory IEC-6 cells were determined by MTT method, Enzyme-linked immunosorbent assay (ELISA), real-time fluorescence quantitative PCR and Western-blot, respectively. The results showed that the survival rate of IEC-6 cells increased gradually with the increase of Astragalin concentration. The survival rates of IEC-6 cells in different dose groups (50 μg/mL and 100 μg/mL) were 90.68% and 95.76% (p<0.05 and p<0.01), respectively. Enzyme-linked immunosorbent assay (ELISA) showed that compared with the LPS group, 50 μg/mL and 100 μg/mL of Astragalin significantly inhibited the secretion level of inflammatory factor IL-6, with inhibition rates of 21.98% (p<0.05) and 29.05% (p<0.01), respectively. The mRNA expression level of IL-6 was decreased by 34.90% (p<0.05) and 41.60% (p<0.01), respectively.The inhibitory rates of TNF-α secretion were 16.25% (p<0.05) and 23.37% (p<0.01), respectively, and the mRNA expression levels were decreased by 34.11% (p<0.05) and 43.84% (p<0.01), respectively. In terms of protein pathway, 100 g/mL of Astragalin showed significant inhibition of P-IKKα/β level 27.46% (p<0.05) and P-IκBα level 41.52% (p<0.05) in NF-κB pathway induced by LPS. This study provides a reliable basis for the development of Astragalin as a potential drug to relieve inflammatory bowel disease.